![Gregorio Guillen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gregorio Guillen active positions
Companies | Position | Start | End |
---|---|---|---|
Catena Biosciences, Inc.
![]() Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Director/Board Member | 17/11/2020 | - |
Chief Operating Officer | 17/11/2020 | - | |
Director of Finance/CFO | 17/11/2020 | - | |
Founder | 17/11/2020 | - | |
Corporate Secretary | 17/11/2020 | - |
Career history of Gregorio Guillen
Statistics
International
United States | 2 |
Operational
Director/Board Member | 1 |
Chief Operating Officer | 1 |
Director of Finance/CFO | 1 |
Sectoral
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Catena Biosciences, Inc.
![]() Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Commercial Services |
- Stock Market
- Insiders
- Gregorio Guillen
- Experience